4.73

1.25% -0.06

Oramed Pharmaceuticals Inc (ORMP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Oramed Pharmaceuticals Inc stock is traded at $4.73, with a volume of 177.85K. It is down -1.25% in the last 24 hours and down -9.21% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Previous Close:

$4.79

Open:

$4.8

24h Volume:

177.85K

Relative Volume:

0.60

Market Cap:

$196.76M

Revenue:

$2.00M

Net Income/Loss:

$109.16M

P/E Ratio:

1.8308

EPS:

2.5835

Net Cash Flow:

$-9.11M

1W Performance:

-0.21%

1M Performance:

-9.21%

6M Performance:

+35.14%

1Y Performance:

+97.08%

1-Day Range:

$4.72

$4.90

1-Week Range:

$4.62

$4.90

52-Week Range:

$2.09

$5.47

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name

Oramed Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

646-844-1164

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY

Employee

Twitter

@OramedPharma

Next Earnings Date

2026-11-12

Latest SEC Filings

ORMP's Discussions on Twitter

Compare ORMP vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORMP Oramed Pharmaceuticals Inc	4.73	196.76M	2.00M	109.16M	-9.11M	2.5835
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight
Apr-20-21	Initiated	Canaccord Genuity	Buy
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy
Mar-11-20	Initiated	Aegis Capital	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy
May-26-16	Reiterated	FBR Capital	Outperform
Dec-01-15	Reiterated	H.C. Wainwright	Buy
Nov-19-15	Initiated	FBR Capital	Outperform
Apr-13-15	Resumed	MLV & Co	Buy
Jan-30-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Initiated	MLV & Co	Buy
Dec-03-13	Initiated	Aegis Capital	Buy

View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

Sep 25, 2026

40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan

Sep 25, 2026

Every outstanding option held by Oramed (ORMP) COO Joshua Hexter was canceled for fully vested shares. - Stock Titan

Sep 25, 2026

Sep 24, 2026

Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu - Barchart.com

Sep 24, 2026

Sep 20, 2026

Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026

Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS

Sep 20, 2026

Sep 18, 2026

Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal

Sep 18, 2026

Sep 17, 2026

Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com South Africa

Sep 17, 2026

Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com

Sep 17, 2026

Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan

Sep 17, 2026

Sep 11, 2026

Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang

Sep 11, 2026

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha

Sep 11, 2026

Sep 10, 2026

Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportLate Stage Breakouts - siam.in

Sep 10, 2026

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine

Sep 10, 2026

Sep 08, 2026

Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan

Sep 08, 2026

Sep 02, 2026

Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn

Sep 02, 2026

Aug 31, 2026

Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de

Aug 31, 2026

Aug 30, 2026